These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 18808446)

  • 1. The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
    Irvine EJ; Yeh CH; Ramsey D; Stirling AL; Higgins PD
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1278-86. PubMed ID: 18808446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.
    Connolly MP; Poole CD; Currie CJ; Marteau P; Nielsen SK
    Digestion; 2009; 80(4):241-6. PubMed ID: 19828955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
    Marakhouski Y; Fixa B; Holomán J; Hulek P; Lukas M; Bátovský M; Rumyantsev VG; Grigoryeva G; Stolte M; Vieth M; Greinwald R;
    Aliment Pharmacol Ther; 2005 Jan; 21(2):133-40. PubMed ID: 15679762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
    Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB; Wedel MK; Xia S; Baker BF
    Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A; Behrens C; Bias P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
    Hartmann F; Stein J;
    Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
    Gibson PR; Fixa B; Pekárková B; Bátovský M; Radford-Smith G; Tibitanzl J; Gabalec L; Florin TH; Greinwald R
    Aliment Pharmacol Ther; 2006 Apr; 23(7):1017-26. PubMed ID: 16573804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV; Cohen RD
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
    Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
    Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.